Large feline case series adds data on off-label oclacitinib use

A new retrospective case series in Veterinary Dermatology adds one of the larger published datasets yet on off-label oclacitinib use in cats with skin disease. Reviewing 238 feline cases, the authors reported that oclacitinib used as monotherapy successfully controlled clinical signs in 59% of cats, while adverse events were generally mild and often improved after dose reduction. The study is notable because Apoquel (oclacitinib) is approved for dogs, not cats, so feline use remains extra-label despite growing clinical interest in JAK inhibition for pruritic and inflammatory skin disease. (deepdyve.com)

Why it matters: For veterinary professionals, the paper helps fill a familiar evidence gap in feline dermatology, where treatment options can be limited and many decisions still rely on smaller studies, case reports, or clinician experience. Earlier feline studies have suggested potential benefit in allergic pruritus and atopic skin syndrome, and this larger retrospective series may give clinicians more confidence in discussing expected response rates, dose adjustments, and monitoring with pet parents, while still reinforcing that use is off-label and safety questions remain. (pmc.ncbi.nlm.nih.gov)

What to watch: Watch for follow-up prospective trials, more standardized safety monitoring, and whether this growing body of feline data changes how dermatologists and general practitioners position oclacitinib in cats. (deepdyve.com)